AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Core Insights - AbbVie is set to present new data from its antibody-drug conjugate (ADC) portfolio at the 2025 ESMO Congress, focusing on treatments for difficult-to-treat cancers [1][2] Group 1: Temab-A Developments - Temab-A, an investigational c-Met directed ADC, will have three oral presentations showcasing its clinical activity across various solid tumors [2][3] - In a Phase 1 study, Temab-A demonstrated an objective response rate (ORR) of 46% in patients with advanced MET-amplified solid tumors, with higher responses in non-small cell lung cancer (NSCLC) at 69% and gastroesophageal adenocarcinoma (GEA) at 71% [4] - In combination with bevacizumab for advanced colorectal cancer (CRC), Temab-A achieved an ORR of 26.7% compared to 0% with the current standard of care [4] Group 2: ABBV-706 Insights - ABBV-706, a SEZ6-directed ADC, is being analyzed in a Phase 1 study for relapsed/refractory small cell lung cancer (R/R SCLC), with findings suggesting it may replace platinum-based standard of care [5][6] - The treatment resulted in rapid clearance of circulating tumor DNA (ctDNA), indicating its potential as an early response marker in SCLC [5] - A Phase 2 study is ongoing to assess ABBV-706 in combination with atezolizumab as a first-line treatment for SCLC [6] Group 3: ESMO Congress Presentations - Key presentations at the ESMO 2025 Congress will include results from studies on Temab-A and ABBV-706, highlighting their efficacy and potential in treating various cancers [7][15]